Global Diabetic Neuropathy Market: Snapshot
A handful of international and local manufacturers with limited shares dominate the global diabetic neuropathy market. This makes the competitive landscape semi-consolidated in nature. The competition among them is intense with most spending time and money on research and development of more effective neuropathy drugs.
The global diabetic neuropathy market is being primarily driven by changing lifestyles which has mostly resulted in unhealthy dietary habits and patterns. As per WHO, about 422 were afflicted by diabetes in 2014. Apart from that, other growth drivers in the market are the approval of novel drugs to treat neuropathic pain and supportive reimbursement policies.
Drugs administered to treat neuropathic pain, however, so far have had only limited success in terms of pain relief. This coupled with erroneous diagnosis or selection of treatment and side effects and rising cost of diabetic neuropathy treatment drugs are posing a hindrance to the market for diabetic neuropathy market.
A report by Transparency Market Research, forecasts the global diabetic neuropathy market to become worth US$5.718 bn by 2024 from US$ 3.6 bn in 2016 by rising at a steady CAGR of 5.4% between 2017 and 2025.
Peripheral Neuropathy to Retain its Dominant Share by Clocking Maximum Growth
Peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy are the prominent disorders in the global diabetic neuropathy market. Peripheral neuropathy, of them, accounts for almost half the share in the market at present. In the near future it is predicted to grow its share marginally by surpassing all other segments in terms of growth rate. The report by TMR predicts the segment to clock a 5.7% CAGR from 2017 to 2025 because of the high prevalence of diabetic neuropathy.
Proximal neuropathy follows peripheral neuropathy when it comes to market share in the global diabetic neuropathy market. This is because proximal diabetic neuropathy is the most commonly found disorder in type 2 diabetes. The segment was worth US$885.6 mn in 2016 and will likely rise to US$1.405 mn by 2025 by expanding at a CAGR of 5.4% from 2017 to 2025.
Major Players Target North America Market Having Large Patient Pool
Key regional segments in the global diabetic neuropathy market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among them, North America accounted for a market leading share of 34.9% in 2016. This is mainly on account of the large pool of patients who have been diagnosed and the expensiveness of therapy. In fact, keen companies are eyeing the market in U.S. in the region to up sales and revenues. The market in North America was worth US$1.071 bn in 2016 and rising at 5.3% CAGR between 2017 and 2025, it is slated to become worth US$1.68 bn by 2025.
Europe trails North America in the global diabetic neuropathy market in terms of size. Its market has been mostly driven by the rising occurrence of diabetic neuropathy and a growing pool of elderly, particularly in countries of Italy, Germany, France, and the U.K. In terms of growth rate, however, the market is Asia Pacific is predicted to outshine all others. Powered primarily by China, Asia Pacific will likely clock a CAGR of 6.7% on account of the growing number of healthcare awareness programs, hospitals equipped with radiology devices to treat diabetic neuropathy, and a large pool of patients.
Some of the key names operating in the market are Pfizer, Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, Lupin Limited, Depomed, Inc., Glenmark Pharmaceuticals Ltd, and Arbor Pharmaceuticals, LLC.
Diabetic Neuropathy Market will Rise Remarkably Owing to Increasing Number of Diabetic Population
The changing lifestyle and increasing adoption of unhealthy eating habits is prognosticated to attract high revenues for the global diabetic neuropathy market. Medications directed to treat neuropathic torment, nonetheless, so far have had just restricted accomplishment as far as relief from discomfort. This combined with wrong finding or choice of treatment and results and increasing expense of diabetic neuropathy treatment drugs are representing an obstruction to the market for diabetic neuropathy market.
Diabetic patients are without a doubt incredibly helpless against genuine inconveniences, whenever tainted by the COVID-19 infection. The disease can cause inner expanding and furthermore increment aggravation among diabetic patients. It is, along these lines, basic for medical clinics, facilities and careful focuses to guarantee that such complexities are alleviated by giving progressed clinical consideration. Luckily, driving makers in the diabetes area have announced that the COVID-19 isn't affecting their present assembling and appropriation abilities for indispensable infusions like insulin.
Diabetic neuropathy alludes to harm of nerves influencing individuals with diabetes. Various kinds of nerve harm lead to various sorts of side effects. Manifestations may go from deadness and agony in one's feet to issues with the day by day elements of one's inward organs, like bladder and heart. Indications change as per the kind of diabetic neuropathy one has. In diabetes patients, undeniable degree of blood glucose, likewise also called glucose, along with significant degrees of fats in the blood can harm one's nerves with time. Expanded predominance of diabetes is probably going to impel development of the diabetic neuropathy market.
One of the significant variables that are assessed to shape the fate of the worldwide diabetic neuropathy market is the ascent in the number maturing individuals who are inclined to experience the ill effects of the said ailment. Besides, ascend in the innovative work exercises for the advancement of new medications to help treat the problem of diabetic neuropathy is probably going to support development of the market over the time of projection.
The Global Diabetic Neuropathy Market is segmented as given below:
by Product |
|
by Treatment Type |
|
by Distribution Channel |
|
by Geography |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Diabetic Neuropathy Market
4. Market Overview
4.1. Introduction
4.1.1 Product Definition
4.1.2 Industry Evolution / Developments
4.2 Overview
4.3 Key Market Indicators
4.3.1 Region/Country Specific
4.3.2 Product/Application/Disease Indication Specific
4.3.3 Target Market Specific – Global Scenario
4.4 Market Dynamics
4.4.1 Drivers
4.4.2 Restraints
4.4.3 Opportunity
4.5 Global Diabetic Neuropathy Market Analysis and Forecasts, 2015–2025
4.5.1 Market Revenue Projections (US$ Mn)
4.6 Diabetic Neuropathy Market - Global Supply Demand Scenario
4.7 Porter’s Five Force Analysis
4.8 Market Outlook
4.9 Diabetic Neuropathy Market : Pipeline Analysis
4.10 Diabetic Neuropathy : Prevalence Data & Percentage of Patient Receiving Treatment
5. Global Diabetic Neuropathy Analysis and Forecasts, By Disorder Type
5.1 Introduction & Definition
5.2 Key Findings / Developments
5.3 Key Trends
5.4 Market Value Forecast By Disorder Type , 2015–2025
5.4.1 Peripheral Neuropathy
5.4.2 Autonomic Neuropathy
5.4.3 Proximal Neuropathy
5.4.4 Focal Neuropathy
5.5 Market Attractiveness By Disorder Type
6. Global Diabetic Neuropathy Analysis and Forecasts, By Treatment Type
6.1 Introduction & Definition
6.2 Key Findings / Developments
6.3 Key Trends
6.4 Market Value Forecast By Treatment Type, 2015–2025
6.4.1 Drug
6.4.1.1 Analgesic
6.4.1.1.1 Topical
6.4.1.1.1.1 Capsaicin
6.4.1.1.1.2 Others
6.4.1.1.2 Opioids
6.4.1.1.2.1 Morphine
6.4.1.1.2.2 Others
6.4.1.1.3 NSAIDs
6.4.1.1.3.1 Ibuprofen
6.4.1.1.3.2 Naproxen
6.4.1.1.3.3 Others
6.4.1.2 Antidepressant
6.4.1.2.1 TCAs
6.4.1.2.1.1 Amitriptyline
6.4.1.2.1.2 Imipramine
6.4.1.2.1.3 Others
6.4.1.2.2 SNRIs
6.4.1.2.2.1 Duloxetine
6.4.1.2.2.2 Others
6.4.1.2.3 SSRIs
6.4.1.2.3.1 Citalopram
6.4.1.2.3.2 Paroxetin
6.4.1.2.3.3 Others
6.4.1.3. Anticonvulsants
6.4.1.3.1 Gabapentin
6.4.1.3.2 Pregabalin
6.4.1.3.3 Topimarate
6.4.1.3.4 Others
6.4.1.4. Other Drugs
6.4.2 Radiotherapy
6.4.2.1 TENS
6.4.2.2 Other
6.4.3 Physiotherapy
6.5 Market Attractiveness By Treatment
7. Global Diabetic Neuropathy Market Analysis and Forecasts, By Distribution Channel
7.1 Introduction & Definition
7.2 Key Findings / Developments
7.3 Key Trends
7.4 Market Value Forecast By Distribution Channel, 2015–2025
7.4.1 Hospitals
7.4.2 Clinics
7.4.3 Retail Pharmacy
7.4.4 Online Pharmacy
7.5 Market Attractiveness By Distribution Channel
8. Global Diabetic Neuropathy Market Analysis and Forecasts, By Region
8.1 Key Findings
8.2 Policies and Regulations
8.3 Market Value Forecast By Region
8.3.1 North America
8.3.2 Europe
8.3.3 Asia Pacific
8.3.4 Latin America
8.3.5 Middle East and Africa
8.4 Market Attractiveness By Country/Region
9. North America Diabetic Neuropathy Market Analysis and Forecast
9.1 Introduction
9.1.1 Key Findings
9.1.2 Policies and Regulations
9.1.3 Key Trends
9.2 Market Value Forecast By Disorder Type, 2015–2025
9.2.1 Peripheral Neuropathy
9.2.2 Autonomic Neuropathy
9.2.3 Proximal Neuropathy
9.2.4 Focal Neuropathy
9.3 Market Value Forecast By Treatment Type, 2015–2025
9.3.1 Drug
9.3.1.1 Analgesic
9.3.1.1.1 Topical
9.3.1.1.1.1 Capsaicin
9.3.1.1.1.2 Others
9.3.1.1.2 Opioids
9.3.1.1.2.1 Morphine
9.3.1.1.2.2 Others
9.3.1.1.3 NSAIDs
9.3.1.1.3.1 Ibuprofen
9.3.1.1.3.2 Naproxen
9.3.1.1.3.3 Others
9.3.1.2. Antidepressant
9.3.1.2.1 TCAs
9.3.1.2.1.1 Amitriptyline
9.3.1.2.1.2 Imipramine
9.3.1.2.1.3 Others
9.3.1.2.2 SNRIs
9.3.1.2.2.1 Duloxetine
9.3.1.2.2.2 Others
9.3.1.2.3 SSRIs
9.3.1.2.3.1 Citalopram
9.3.1.2.3.2 Paroxetin
9.3.1.2.3.3 Others
9.3.1.3. Anticonvulsants
9.3.1.3.1 Gabapentin
9.3.1.3.2 Pregabalin
9.3.1.3.3 Topimarate
9.3.1.3.4 Others
9.3.1.4. Other Drugs
9.4.2. Radiotherapy
9.4.2.1. TENS
9.4.2.2. Other
9.4.3. Physiotherapy
9.4. Market Value Forecast By Distribution Channel, 2015–2025
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Retail Pharmacy
9.4.4. Online Pharmacy
9.5. Market Value Forecast By Country , 2015–2025
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Disorder Type
9.6.2. By Treatment Type
9.6.3. By Distribution Channel
9.6.5. By Country
10. Europe Diabetic Neuropathy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Key Trends
10.2. Market Value Forecast By Disorder Type, 2015-2025
10.2.1. Peripheral Neuropathy
10.2.2. Autonomic Neuropathy
10.2.3. Proximal Neuropathy
10.2.4. Focal Neuropathy
10.3. Market Value Forecast By Treatment Type, 2015–2025
10.3.1. Drug
10.3.1.1. Analgesic
10.3.1.1.1 Topical
10.3.1.1.1.1 Capsaicin
10.3.1.1.1.2 Others
10.3.1.1.2 Opioids
10.3.1.1.2.1 Morphine
10.3.1.1.2.2 Others
10.3.1.1.3 NSAIDs
10.3.1.1.3.1 Ibuprofen
10.3.1.1.3.2 Naproxen
10.3.1.1.3.3 Others
10.3.1.2 Antidepressant
10.3.1.2.1 TCAs
10.3.1.2.1.1 Amitriptyline
10.3.1.2.1.2 Imipramine
10.3.1.2.1.3 Others
10.3.1.2.2 SNRIs
10.3.1.2.2.1 Duloxetine
10.3.1.2.2.2 Others
10.3.1.2.3 SSRIs
10.3.1.2.3.1 Citalopram
10.3.1.2.3.2 Paroxetin
10.3.1.2.3.3 Others
10.3.1.3 Anticonvulsants
10.3.1.3.1 Gabapentin
10.3.1.3.2 Pregabalin
10.3.1.3.3 opimarate
10.3.1.3.4 Others
10.3.1.4 Other Drugs
10.3.2 Radiotherapy
10.3.2.1 TENS
10.3.2.2 Other
10.4.3 Physiotherapy
10.4 Market Value Forecast By Distribution Channel, 2015–2025
10.4.1 Hospitals
10.4.2 Clinics
10.4.3 Retail Pharmacy
10.4.4 Online Pharmacy
10.5 Market Value Forecast By Country, 2015–2025
10.5.1 Germany
10.5.2 France
10.5.3 U.K.
10.5.4 Spain
10.5.5 Italy
10.5.6 Russia
10.5.7 Rest of Europe
10.6 Market Attractiveness Analysis
10.6.1 By Disorder Type
10.6.2 By Treatment Type
10.6.3 By Distribution Channel
10.6.4 By Country
11. Asia Pacific Diabetic Neuropathy Market Analysis and Forecast
11.1 Introduction
11.1.1 Key Findings
11.1.2 Policies and Regulations
11.1.3 Key Trends
11.2 Market Value Forecast By Disorder Type , 2015–2025
11.2.1 Peripheral Neuropathy
11.2.2 Autonomic Neuropathy
11.2.3 Proximal Neuropathy
11.2.4 Focal Neuropathy
11.3 Market Value Forecast By Treatment Type, 2015–2025
11.3.1 Drug
11.3.1.1 Analgesic
11.3.1.1.1 Topical
11.3.1.1.1.1 Capsaicin
11.3.1.1.1.2 Others
11.3.1.1.2 Opioids
11.3.1.1.2.1 Morphine
11.3.1.1.2.2 Others
11.3.1.1.3 NSAIDs
11.3.1.1.3.1 Ibuprofen
11.3.1.1.3.2 Naproxen
11.3.1.1.3.3 Others
11.3.1.2 Antidepressant
11.3.1.2.1 TCAs
11.3.1.2.1.1 Amitriptyline
11.3.1.2.1.2 Imipramine
11.3.1.2.1.3 Others
11.3.1.2.2 SNRIs
11.3.1.2.2.1 Duloxetine
11.3.1.2.2.2 Others
11.3.1.2.3 SSRIs
11.3.1.2.3.1 Citalopram
11.3.1.2.3.2 Paroxetin
11.3.1.2.3.3 Others
11.3.1.3 Anticonvulsants
11.3.1.3.1 Gabapentin
11.3.1.3.2 Pregabalin
11.3.1.3.3 Topimarate
11.3.1.3.4 Others
11.3.1.4 Other Drugs
11.3.2 Radiotherapy
11.3.2.1 TENS
11.3.2.2 Other
11.3.3 Physiotherapy
11.4 Market Value Forecast By Distribution Channel , 2015–2025
11.4.1 Hospitals
11.4.2 Clinics
11.4.3 Retail Pharmacy
11.4.4 Online Pharmacy
11.5 Market Value Forecast By Country , 2015–2025
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4 Australia & New Zealand
11.5.5 Rest of Asia Pacific
11.6 Market Attractiveness Analysis
11.6.1 By Disorder Type
11.6.2 By Treatment Type
11.6.3 By Distribution Channel
11.6.4 By Country
12. Latin America Diabetic Neuropathy Market Analysis and Forecast
12.1 Introduction
12.1.1 Key Findings
12.1.2 Policies and Regulations
12.1.3 Key Trends
12.2 Market Value Forecast By Disorder Type , 2015–2025
12.2.1 Peripheral Neuropathy
12.2.2 Autonomic Neuropathy
12.2.3 Proximal Neuropathy
12.2.4 Focal Neuropathy
12.3 Market Value Forecast By Treatment Type, 2015–2025
12.3.1 Drug
12.3.1.1 Analgesic
12.3.1.1.1 Topical
12.3.1.1.1.1 Capsaicin
12.3.1.1.1.2 Others
12.3.1.1.2 Opioids
12.3.1.1.2.1 Morphine
12.3.1.1.2.2 Others
12.3.1.1.3 NSAIDs
12.3.1.1.3.1 Ibuprofen
12.3.1.1.3.2 Naproxen
12.3.1.1.3.3 Others
12.3.1.2 Antidepressant
12.3.1.2.1 TCAs
12.3.1.2.1.1 Amitriptyline
12.3.1.2.1.2 Imipramine
12.3.1.2.1.3 Others
12.3.1.2.2 SNRIs
12.3.1.2.2.1 Duloxetine
12.3.1.2.2.2 Others
12.3.1.2.3 SSRIs
12.3.1.2.3.1 Citalopram
12.3.1.2.3.2 Paroxetin
12.3.1.2.3.3 Others
12.3.1.3 Anticonvulsants
12.3.1.3.1 Gabapentin
12.3.1.3.2 Pregabalin
12.3.1.3.3 Topimarate
12.3.1.3.4 Others
12.3.1.4 Other Drugs
12.3.2 Radiotherapy
12.3.2.1 TENS
12.3.2.2 Other
12.3.3 Physiotherapy
12.4 Market Value Forecast By Distribution Channel , 2015–2025
12.4.1 Hospitals
12.4.2 Clinics
12.4.3 Retail Pharmacy
12.4.4 Online Pharmacy
12.5 Market Value Forecast By Country , 2015–2025
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Rest of Latin America
12.6 Market Attractiveness Analysis
12.6.1 By Disorder Type
12.6.2 By Treatment Type
12.6.3 By Distribution Channel
12.6.4 By Country
13. Middle East and Africa Diabetic Neuropathy Market Analysis and Forecast
13.1. Introduction
13.1.1 Key Findings
13.1.2 Policies and Regulations
13.1.4 Key Trends
13.2. Market Value Forecast By Disorder Type, 2015–2025
13.2.1 Peripheral Neuropathy
13.2.2 Autonomic Neuropathy
13.2.3 Proximal Neuropathy
13.2.4 Focal Neuropathy
13.3. Market Value Forecast By Treatment Type, 2015–2025
13.3.1 Drug
13.3.1.1 Analgesic
13.3.1.1.1 Topical
13.3.1.1.1.1 Capsaicin
13.3.1.1.1.2 Others
13.3.1.1.2 Opioids
13.3.1.1.2.1 Morphine
13.3.1.1.2.2 Others
13.3.1.1.3 NSAIDs
13.3.1.1.3.1 Ibuprofen
13.3.1.1.3.2 Naproxen
13.3.1.1.3.3 Others
13.3.1.2 Antidepressant
13.3.1.2.1 TCAs
13.3.1.2.1.1 Amitriptyline
13.3.1.2.1.2 Imipramine
13.3.1.2.1.3 Others
13.3.1.2.2 SNRIs
13.3.1.2.2.1 Duloxetine
13.3.1.2.2.2 Others
13.3.1.2.3 SSRIs
13.3.1.2.3.1 Citalopram
13.3.1.2.3.2 Paroxetin
13.3.1.2.3.3 Others
13.3.1.3 Anticonvulsants
13.3.1.3.1 Gabapentin
13.3.1.3.2 Pregabalin
13.3.1.3.3 Topimarate
13.3.1.3.4 Others
13.3.1.4 Other Drugs
13.3.2 Radiotherapy
13.3.2.1 TENS
13.3.2.2 Other
13.3.3 Physiotherapy
13.4 Market Value Forecast By Distribution Channel , 2015–2025
13.4.1 Hospitals
13.4.2 Clinics
13.4.3 Retail Pharmacy
13.4.4 Online Pharmacy
13.5 Market Value Forecast By Country , 2015–2025
13.5.1 GCC Countries
13.5.2 South Africa
13.5.3 Rest of Middle East and Africa
13.6 Market Attractiveness Analysis
13.6.1 By Disorder Type
13.6.2 By Treatment
13.6.3 By Distribution Channel
13.6.4 By Country
14. Competition Landscape
14.1 Market Player – Competition Matrix (By Tier and Size of companies)
14.2 Market Share Analysis By Company, 2016
14.3 Company Profiles
14.3.1 Johnson & Johnson (Janssen Global Services, LLC)
14.3.1.1 Overview
14.3.1.2 Financials
14.3.1.3 Recent Developments
14.3.1.4 Strategy
14.3.2. Boehringer Ingelheim GmbH
14.3.2.1 Overview
14.3.2.2 Financials
14.3.2.3 Recent Developments
14.3.2.4 Strategy
14.3.3 NeuroMetrix, Inc.
14.3.3.1 Overview
14.3.3.2 Financials
14.3.3.3 Recent Developments
14.3.3.4 Strategy
14.3.4 Eli Lilly and Company
14.3.4.1 Overview
14.3.4.2 Financials
14.3.4.3 Recent Developments
14.3.4.4 Strategy
14.3.5 GlaxoSmithKline plc.
14.3.5.1 Overview
14.3.5.2 Financials
14.3.5.3 Recent Developments
14.3.5.4 Strategy
14.3.6 Lupin Limited
14.3.6.1 Overview
14.3.6.2 Financials
14.3.6.3 Recent Developments
14.3.6.4 Strategy
14.3.7 Pfizer Inc.
14.3.7.1 Overview
14.3.7.2 Financials
14.3.7.3 Recent Developments
14.3.7.4 Strategy
14.3.8 Astellas Pharma Inc.,
14.3.8.1 Overview
14.3.8.2 Financials
14.3.8.3 Recent Developments
14.3.8.4 Strategy
14.3.9 Glenmark Pharmaceuticals Ltd
14.3.9.1 Overview
14.3.9.2 Financials
14.3.13.3 Recent Developments
14.3.9.4 Strategy
14.3.10 Arbor Pharmaceuticals, LLC
14.3.10.1 Overview
14.3.10.2 Financials
14.3.13.3 Recent Developments
14.3.10.4 Strategy
14.3.11 Depomed, Inc.
14.3.10.1 Overview
14.3.10.2 Financials
14.3.13.3 Recent Developments
14.3.10.4 Strategy
List of Tables
Table 1: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
Table 2: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 3: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 4: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
Table 5: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
Table 6: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
Table 7: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
Table 8: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
Table 9: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
Table 10: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
Table 11: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
Table 12: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
Table 13: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
Table 14: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 15: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 16: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 17: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
Table 18: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 19: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 20: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
Table 21: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
Table 22: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
Table 23: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
Table 24: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
Table 25: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
Table 26: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
Table 27: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
Table 28: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
Table 29: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
Table 30: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 31: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 32: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
Table 33: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 34: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 35: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
Table 36: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
Table 37: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
Table 38: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
Table 39: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
Table 40: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
Table 41: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
Table 42: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
Table 43: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
Table 44: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
Table 45: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 46: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 47: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
Table 48: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 49: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 50: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
Table 51: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
Table 52: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
Table 53: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
Table 54: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
Table 55: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
Table 56: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
Table 57: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
Table 58: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
Table 59: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
Table 60: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 61: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 62: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
Table 63: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 64: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 65: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
Table 66: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
Table 67: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
Table 68: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
Table 69: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
Table 70: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
Table 71: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
Table 72: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
Table 73: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
Table 74: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
Table 75: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 76: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 77: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
Table 78: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 79: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 80: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
Table 81: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
Table 82: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
Table 83: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
Table 84: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
Table 85: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
Table 86: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
Table 87: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
Table 88: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
Table 89: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
Table 90: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
List of Figures
Figure 1: Global Diabetic Neuropathy, Market Size (US$ Mn) Forecast, 2015–2025
Figure 2: Global Diabetic Neuropathy Market Value Share, by Disorder Type, for 2017 and 2025
Figure 3: Global Diabetic Neuropathy Market Attractiveness Analysis, by Disorder Type, 2017–2025
Figure 4: Global Peripheral Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 5: Global Autonomic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 6: Global Proximal Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 7: Global Focal Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 8: Global Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
Figure 9: Global Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2017–2025
Figure 10: Global Analgesic Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 11: Global Antidepressant Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 12: Global Anticonvulsant Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 13: Global Other Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 14: Global Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
Figure 15: Global Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 16: Global Diabetic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2015–2025
Figure 17: Global Diabetic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2015–2025
Figure 18: Global Diabetic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
Figure 19: Global Diabetic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacy, 2015–2025
Figure 20: Global Diabetic Neuropathy Market Value Share, by Region, 2017 and 2025
Figure 21: Global Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2016–2024
Figure 22: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 23: North America Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
Figure 24: North America Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
Figure 25: North America Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
Figure 26: North America Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
Figure 27: North America Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
Figure 28: North America Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
Figure 29: North America Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
Figure 30: North America Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
Figure 31: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 32: Europe Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
Figure 33: Europe Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
Figure 34: Europe Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
Figure 35: Europe Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
Figure 36: Europe Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
Figure 37: Europe Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
Figure 38: Europe Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
Figure 39: Europe Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
Figure 40: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth Projections (%), 2015–2025
Figure 41: Asia Pacific Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
Figure 42: Asia Pacific Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
Figure 43: Asia Pacific Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
Figure 44: Asia Pacific Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
Figure 45: Asia Pacific Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
Figure 46: Asia Pacific Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
Figure 47: Asia Pacific Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
Figure 48: Asia Pacific Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
Figure 49: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth Projections (%), 2015–2025
Figure 50: Latin America Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
Figure 51: Latin America Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
Figure 52: Latin America Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
Figure 53: Latin America Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
Figure 54: Latin America Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
Figure 55: Latin America Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
Figure 56: Latin America Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
Figure 57: Latin America Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
Figure 58: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth Projections (%), 2015–2025
Figure 59: Middle East & Africa Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
Figure 60: Middle East & Africa Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
Figure 61: Middle East & Africa Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
Figure 62: Middle East & Africa Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
Figure 63: Middle East & Africa Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
Figure 64: Middle East & Africa Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
Figure 65: Middle East & Africa Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
Figure 66: Middle East & Africa Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
Figure 67: Global Diabetic Neuropathy Market Share Analysis, by Company, 2016